CD9-MM196-100μg / 询价
CD9-MM196-500μg / 询价
CD9-MM196-500μgx2 / 询价
表达区间及表达系统(Source)
|
Recombinant Mouse CD96/TACTILE Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Val22-Met536 [Accession | Q3U0X8]. |
分子量大小(Molecular Weight)
|
The protein has a predicted MW of 57.9 kDa. Due to glycosylation, the protein migrates to 90-130 kDa based on Bis-Tris PAGE result. |
纯度(Purity)
|
> 95% as determined by Bis-Tris PAGE |
内毒素(Endotoxin)
|
Less than 1EU per μg by the LAL method. |
制剂(Formulation)
|
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
重构方法(Reconstitution)
|
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
存储(Storage)
|
-20 to -80°C for 12 months as supplied from date of receipt. |
Recombinant Mouse CD96/TACTILE Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Val22-Met536 [Accession | Q3U0X8].
The protein has a predicted MW of 57.9 kDa. Due to glycosylation, the protein migrates to 90-130 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
CD96 molecule; CD96; DKFZp667E2122; TACTILE
(1) Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.
CD9-MM196-100μg / 询价
CD9-MM196-500μg / 询价
CD9-MM196-500μgx2 / 询价
货号* | 规格* | 名称 | 数量* | |
---|---|---|---|---|
货号* | 名称 | 批号* | |
---|---|---|---|